![](https://www.lachmanconsultants.com/wp-content/uploads/2019/01/iStock-172858384-dec13.jpg)
FDA Withdraws Proposed Labeling Rule – Finally!
After just over five years, the FDA is officially withdrawing its controversial proposed labeling rule for generic drugs. The advance publication notice in the Federal Register can be found (here). The proposed rule would have permitted ANDA holders to unilaterally revise its labeling via a CBE-0 supplement to include new or different safety information or […]